____________________________________________________________________________ Anxiety Disorders PYFL15AD — 15 CE HOURS R elease D ate : 05/01/25 E xpiration D ate : 04/30/28
Anxiety Disorders
13. Devise a strategy for management and follow-up designed to improve outcomes. 14. Provide patient education more effectively, in relation to specific anxiety disorders. 15. Address the efficacy, safety and limitations of novel, emerg- ing, and alternative/complementary approaches to the treatment of anxiety disorders. Faculty Mark Rose, BS, MA, LP , is a licensed psychologist in the State of Minnesota with a private consulting practice and a medical research analyst with a biomedical communications firm. Earlier healthcare technology assessment work led to medical device and pharmaceutical sector experience in new product development involving cancer ablative devices and pain therapeutics. Along with substantial experience in addiction research, Mr. Rose has contributed to the authorship of numerous papers on CNS, oncology, and other medical disorders. He is the lead author of papers published in peer-reviewed addiction, psychiatry, and pain medicine journals and has written books on prescription opioids and alcoholism published by the Hazelden Foundation. He also serves as an Expert Advisor and Expert Witness to law firms that represent disability claimants or criminal defendants on cases related to chronic pain, psychiatric/substance use disorders, and acute pharmacologic/toxicologic effects. Mr. Rose is on the Board of Directors of the Minneapolis-based International Institute of Anti-Aging Medicine and is a member of several professional organizations. Faculty Disclosure Contributing faculty, Mark Rose, BS, MA, LP, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned. Division Planners John M. Leonard, MDJohn V. Jurica, MD, MPHMargo A. Halm, RN, PhD, ACNS-BC, FAANRandall L. Allen, PharmD Senior Director of Development and Academic Affairs Sarah Campbell Division Planners/Director Disclosure The division planners and director have disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
Audience This course is designed for health and mental health providers involved in the identification, treatment, and care of patients with anxiety disorder. Course Objective The purpose of this course is to provide healthcare professionals with the knowledge and skills necessary to appropriately identify and treat patients with anxiety disorders, addressing knowledge gaps, enhancing clinical skills, and improving patient outcomes. Learning Objectives Upon completion of this course, you should be able to: 1. Review basic concepts related to anxiety disorders, includ- ing safety behaviors/signals and primaryfeatures. 2. Outline the epidemiology of anxiety disorders in the United States. 3. Describe general risk factors for and comorbidities of anxiety disorders. 4. Describe risk factors for and the clinical course of specific anxiety disorders. 5. Discuss the pathogenesis of anxiety disorders in relation to contributing genetic, physiologic, and psychologic factors. 6. Review the pathophysiology of specific anxiety disorders, including social anxiety disorder,agoraphobia, and specific phobia. 7. Apply the clinical and diagnostic criteria for anxiety dis- orders presented in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 8. Analyze key components of screening and select appropri- ate screening tools for identification of anxiety disorders. 9. Conduct an informed clinical evaluation and select labora- tory testing, in consideration of the differential diagnosis of anxiety disorders. 10. Describe general treatment considerations for anxiety disorders, including predictors of response or nonresponse to therapy. 11. Discuss the role and efficacy of psychotherapy approaches in the treatment of anxiety disorders. 12. Select a pharmacotherapy option appropriate to a given patient’s specific diagnosis, age, and comorbidities.
EliteLearning.com/Psychology 81 Mention of commercial products does not indicate endorsement.
Powered by FlippingBook